EP Patent

EP3122334A1 — Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use

Assigned to Dot Therapeutics 1 Inc · Expires 2017-02-01 · 9y expired

What this patent protects

The invention relates to a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof for the treatment of cancer and a process for its preparation. The invention also relates to administering the pharmaceutical composition to a patient accordi…

USPTO Abstract

The invention relates to a pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt thereof for the treatment of cancer and a process for its preparation. The invention also relates to administering the pharmaceutical composition to a patient according to an intermittent dosing regimen.

Drugs covered by this patent

Patent Metadata

Patent number
EP3122334A1
Jurisdiction
EP
Classification
—
Expires
2017-02-01
Drug substance claim
No
Drug product claim
No
Assignee
Dot Therapeutics 1 Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.